Pancreatic Cancer Research

ResearcherUniversity of TsukubaActive in the last 2 years

Ryoichi Miyamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0687-6225; OpenAlex author ID A5031064743. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 12

  1. Analysis of the relationship between immunological microenvironment and prognosis in pancreatic cancer. Co-author DOI 10.62347/wylc8512↗
  2. Prognostic factors based on histological categorization of desmoplastic reactions in pancreatic cancer. Co-author DOI 10.1002/wjs.12269↗
  3. Prognostic Value of Peritoneal Lavage Cytology in Potentially Resectable Pancreatic Cancer Stratified by Cytologic Status. Co-author DOI 10.21873/cdp.10221↗
  4. Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Left-Sided Pancreatic Cancer Based on Tumor Location. Co-author DOI 10.1245/s10434-021-11108-5↗
  5. Three-dimensional remnant pancreatic volume ratio indicates postoperative pancreatic exocrine insufficiency in pancreatic cancer patients after distal pancreat… Co-author DOI 10.1016/j.pan.2020.06.018↗
  6. Remnant pancreatic volume as an indicator of poor prognosis in pancreatic cancer patients after resection. Co-author DOI 10.1016/j.pan.2019.05.464↗
  7. Three-Dimensional Remnant Pancreatic Volumetry Predicts Postoperative Pancreatic Fistula in Pancreatic Cancer Patients after Pancreaticoduodenectomy. Co-author DOI 10.1159/000495406↗
  8. Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000697↗
  9. Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer. Co-author DOI 10.1111/cas.12888↗
  10. Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. Co-author DOI 10.1038/bjc.2014.49↗
  11. Histological advantages of the tumor graft: a murine model involving transplantation of human pancreatic cancer tissue fragments. Co-author DOI 10.1097/mpa.0b013e318296f866↗
  12. Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer. Co-author DOI 10.1111/cas.12198↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuji Suzuki · 2 shared papers, 2024–2026 · strength 0.51
  2. Yuichi Nagakawa · 2 shared papers, 2024–2026 · strength 0.51
  3. Mitsugi Shimoda · 2 shared papers, 2024–2026 · strength 0.51
  4. Toshitaka Nagao · 2 shared papers, 2024–2026 · strength 0.51
  5. Nobuhiro Ohkohchi · 6 shared papers, 2013–2019 · strength 0.44
  6. Tatsuya Oda · 6 shared papers, 2013–2020 · strength 0.39
  7. Amane Takahashi · 2 shared papers, 2022–2023 · strength 0.35
  8. Toshiro Ogura · 2 shared papers, 2022–2023 · strength 0.35
  9. Hiroyuki Ishida · 2 shared papers, 2022–2023 · strength 0.35
  10. Minoru Tanabe · 2 shared papers, 2022–2023 · strength 0.35
  11. Yoshiyuki Kawashima · 2 shared papers, 2022–2023 · strength 0.35
  12. Masahiro Shiihara · 1 shared paper, 2026 · strength 0.30
  13. Yusuke Ohara · 5 shared papers, 2013–2017 · strength 0.23
  14. Tsuyoshi Enomoto · 5 shared papers, 2013–2017 · strength 0.23
  15. Yoshimasa Akashi · 5 shared papers, 2013–2017 · strength 0.23
  16. Takahiro Einama · 1 shared paper, 2024 · strength 0.21
  17. Katsumi Amikura · 1 shared paper, 2022 · strength 0.16
  18. Naoya Ikeda · 1 shared paper, 2020 · strength 0.16
  19. Tomohiro Kurokawa · 3 shared papers, 2014–2017 · strength 0.16
  20. Osamu Shimomura · 1 shared paper, 2016 · strength 0.05
  21. Nobuhiro Ohkochi · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.